Voisin Consulting’s comments on the proposed European Regulation on advanced therapy products issued by the European Commission

Post thumbnail Voisin Consulting’s comments on the proposed European Regulation on advanced therapy products issued by the European Commission

This document summarizes VCLS’s comments on the Draft Regulation and on the Consultation Paper, published by the European Community on 4 May 2005. They concern the scope of the Regulation, the composition of the Committee for Advanced Therapies, the requirements for a Marketing Authorization and the Incentives.

2005 – European Comission

Download the full publication now

Fill in the form to download the content

*I have read and agreed to the Terms of Use and the Privacy Policy.Yes, I would like to receive communications regarding VCLS services and events

Voisin Consulting’s comments on the proposed European Regulation on advanced therapy products issued by the European Commission

Download the full publication now

Sponsors of Clinical Trials in the EU/EEA – Call for Action!

Creating a complex IND whilst safeguarding confidential data between a CGT spin-off and CDMO

Navigating the FDA Draft Guidance Document “Manufacturing Changes and Comparability for Human Cellular and Gene…

Key CMC and NC considerations for cell and gene therapy development

Voisin Consulting’s comments on the proposed European Regulation on advanced therapy products issued by the European Commission

Download the full publication now

More resources

Sponsors of Clinical Trials in the EU/EEA – Call for Action!

Creating a complex IND whilst safeguarding confidential data between a CGT spin-off and CDMO

Navigating the FDA Draft Guidance Document “Manufacturing Changes and Comparability for Human Cellular and Gene…

Key CMC and NC considerations for cell and gene therapy development